IN10018 in Combination With Standard Chemotherapy in High-grade Serous Epithelial Ovarian Cancer

This is a phase Ib/II, open label clinical study to evaluate the safety, tolerability and antitumor activities of IN10018 in combination with standard chemotherapy in subjects with high-grade serous ovarian cancer (including fallopian tube cancer and primary peritoneum cancer, collectively defined as ovarian cancer).

Trial Details

NCT ID
NCT05551507
Phase
PHASE1 / PHASE2
Sponsor
InxMed (Shanghai) Co., Ltd.
Status
RECRUITING
Cancer Type
Ovarian Cancer
Interventions
  • IN10018 in combination with PLD
Locations (sample)
  • Anyang, China|36.096,114.38278
  • Beijing, China|39.9075,116.39723
  • Changsha, China|28.19874,112.97087
  • Fuzhou, China|26.06139,119.30611
  • Hangzhou, China|30.29365,120.16142

Key Eligibility Criteria

  • Ability to understand and willingness to sign informed consent(s). Signed informed consent must be obtained before any study specific procedures, e…
  • Female subjects ≥ 18 years at the time of signing informed consent.
  • Histologically confirmed epithelia ovarian cancer, fallopian tube cancer or primary peritoneum cancer with the subtype limited to high-grade serous…
  • Subjects with platinum-resistant disease, defined as having relapsed or progressed between 1- 6 months after completion of prior platinum-based the…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →